August 28, 2023 - August 30, 2023

Mono Pharmacare IPO Review & Recommendations

Dilip Davda has given "May Apply" recommendation to Mono Pharmacare IPO.

Mono Pharmacare IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	0	1	0	0	0
%	0.00	100.00	0.00	0.00	0.00

Mono Pharmacare IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Dilip Davda	May Apply

Mono Pharmacare IPO Review by Dilip Davda (May apply)

[Dilip Davda] The company is a distributor for many giant pharma companies and has been doing well for the reported periods. Based on FY23 earnings, the issue appears aggressively priced. Well-informed investors may park funds for the medium to long-term rewards. Read detail review...

Mono Pharmacare IPO Peer Comparison

Mono Pharmacare Limited peer comparison with similar listed entities. (Standalone) (As on March 31, 2023)

Company Name	EPS (Rs)		NAV (per share) (Rs)	P/E (x)	RoNW (%)
Company Name	EPS Basic	EPS Diluted	NAV (per share) (Rs)	P/E (x)	RoNW (%)
Mono Pharmacare Limited	1.99	1.99	19.92		9.01
Chandra Bhagat Pharma Limited	1.20	1.20	36.42	112.50	3.29

Notes:

All the financial information for listed industry peers mentioned above is on a standalone basis sourced from the Annual Reports of the peer company uploaded on the BSE SME website for the year ended March 31, 2023.
P/E Ratio has been computed based on the closing market price of equity shares on the BSE on March 31, 2023, divided by the Diluted EPS of August 11, 2023.
RoNW is computed as net profit after tax divided by the closing net worth. Net worth has been computed as the sum of share capital and reserves and surplus.
NAV is computed as the closing net worth divided by the weighted average number of equity shares.

Mono Pharmacare IPO Review by Members

Mono Pharmacare IPO Reviews, analysis and views by popular members. Read Mono Pharmacare Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Mono Pharmacare IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	3	0	1	1
%	60.00	0.00	20.00	20.00

Member	Review
B.M.SURANA IPO Guru (2700+ Posts, 5300+ Likes)	Neutral Kuchh dum nahin lagta. Risk lene wale Apni Sochen....... 2 August 28, 2023 1:45:18 PM
IPOmentor (200+ Posts)	Avoid High valuation. August 27, 2023 10:25:54 AM
P.S	Apply for Long Term at Cut-off Price Must subscribe. August 25, 2023 4:12:29 PM
APL	Apply for Long Term at Cut-off Price MUST SUBSCRIBE FOR LONG TERM. POSITIVE VISION August 25, 2023 12:54:04 PM
MONO	Apply for Long Term at Cut-off Price A company with Good growth and Vision August 24, 2023 11:16:19 PM

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

1 Comments

1. KHL Link|August 28, 2023 4:59:45 PM

Avoid. Why to invest in such company, I am not agree with Dilip Sir. Big No for MPL.